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TheAMP-activated protein kinase (AMPK) is a sensor of cellular energy status. It is activated, by amechanism
requiring the tumor suppressor LKB1, bymetabolic stresses that increase cellular ADP:ATP and/or AMP:ATP
ratios. Once activated, it switches on catabolic pathways that generate ATP, while switching off biosynthetic
pathways and cell-cycle progress. These effects suggest that AMPK activators might be useful for treatment
and/or prevention of type 2 diabetes and cancer. Indeed, AMPK is activated by the drugs metformin and
salicylate, the latter being themajor breakdown product of aspirin. Metformin is widely used to treat diabetes,
while there is epidemiological evidence that both metformin and aspirin provide protection against cancer.
We review the mechanisms of AMPK activation by these and other drugs, and by natural products derived
from traditional herbal medicines.The AMP-activated protein kinase (AMPK) is a highly conserved
sensor of cellular energy status, and genes encoding the three
subunits of the kinase are found in essentially all eukaryotic
genomes (Hardie, 2011). AMPK is switched on by metabolic
stresses and xenobiotic compounds that cause a cellular energy
imbalance, which is detected as increases in the ratios of
ADP:ATP and AMP:ATP. Because the energy status of the cell
is a crucial factor in all aspects of cell function, it is not surprising
that AMPK has many downstream targets whose phosphoryla-
tion mediates dramatic changes in cell metabolism, cell growth,
and other functions. In general, AMPK switches on catabolic
processes that provide alternative pathways to generate ATP,
while switching off anabolic pathways and other processes
consuming ATP, thus acting to restore cellular energy homeo-
stasis. The kinase evolved in single-celled eukaryotes and is still
involved in multicellular organisms in regulating energy balance
in a cell-autonomous manner. However, it is now clear that
new functions were acquired during the development of meta-
zoans so that AMPK is also regulated by hormones and adipo-
kines that regulate energy balance at the whole body level,
a topic reviewed in more detail elsewhere (Hardie et al., 2012).
Metabolic disorders, such as obesity and type 2 diabetes, which
are becoming increasingly prevalent in modern society, are
essentially problems caused by a positive energy balance, and
it was predicted—in a review written in the 1990s (Winder and
Hardie, 1999)—that activators of AMPK might be useful for
treating these disorders. This suggestion has been taken up by
the pharmaceutical industry, which has been developing novel
activators, but what was not predicted was that several existing
drugs, aswell asmany natural plant products with reputed health
benefits, would also turn out to be AMPK activators. Findings
that AMPK caused inhibition of progress through the cell cycle
(Imamura et al., 2001), and that the mechanism of AMPK acti-
vation required the presence of the tumor suppressor LKB1
(Hawley et al., 2003; Woods et al., 2003; Shaw et al., 2004),
also introduced the idea (discussed further below) that AMPK
activators might be useful in the prevention and/or treatment of
cancer.1222 Chemistry & Biology 19, October 26, 2012 ª2012 Elsevier Ltd AThemajor aim of this review is to discuss the various drugs and
xenobiotics that regulate AMPK, to clarify the various mecha-
nisms by which they achieve this, and to discuss the evidence
that these agents might be useful in the treatment of obesity,
type 2 diabetes, and cancer.
AMPK: Subunit Structure and Regulation
AMPK appears to exist in all eukaryotes as heterotrimeric
complexes composed of a catalytic a subunit and regulatory
b and g subunits (Figure 1). In mammals all three subunits have
multiple isoforms (a1, a2; b1, b2; g1, g2, and g3) encoded by
distinct genes, and all twelve possible heterotrimeric combina-
tions are able to form when these are coexpressed in cells.
The functions of the different subunit isoforms remain unclear,
although there is tissue-specific expression of some isoforms,
and (as discussed below) there is evidence that different iso-
forms may target complexes to specific subcellular locations.
Moreover, some AMPK-activating drugs show selectivity for
certain isoform combinations.
The Catalytic a Subunits
The catalytic subunits are encoded by two alternate genes in
mammals (PRKAA1 and PRKAA2 in humans). The a1 isoform
appears to be universally expressed, whereas a2 is more abun-
dant in tissues such as skeletal and cardiac muscle, and
appears to be absent in cells of the blood and endothelial cell
lineages. Both isoforms contain conventional serine/threonine
kinase domains at the N terminus, and their kinase activity is
increased >100-fold by phosphorylation of a conserved threo-
nine residue within the ‘‘activation loop,’’ a sequence segment
also critically involved in regulation of many other kinases (John-
son et al., 1996). This threonine residue is usually referred to as
Thr-172 because of its position in the original rat sequence
(Hawley et al., 1996), although the exact residue numbering
may differ in other species. The upstream kinases that phos-
phorylate this site were first identified by whole kinome screens
in yeast (Saccharomyces cerevisiae), where three protein
kinases with partially redundant functions were identified
(Hong et al., 2003; Nath et al., 2003; Sutherland et al., 2003).ll rights reserved
Figure 1. Domain Structure of the a, b, and g Subunits of AMPK
and Their Isoforms
a-subunits: AID, autoinhibitory domain; a-CTD, C-terminal domain;
b-subunits: CBM, carbohydrate-binding module; b-CTD, C-terminal domain;
g subunits: CBS1, CBS2, CBS3, CBS4, cystathione b-synthase repeats; g2-
NTD, N-terminal extension of ‘‘long’’ version of g2 subunit; g3-NTD, N-terminal
extension of ‘‘long’’ version of g3 subunit.
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kinome, searching using their kinase domain sequences re-
vealed that the closest matches were to LKB1 and the two iso-
forms of the calmodulin-dependent kinase kinases, CaMKKa
and CaMKKb. Indeed, all three of these can act as upstream
kinases in mammalian cells, although CaMKKa is less active
that the other two (Hawley et al., 2003, 2005; Woods et al.,
2003, 2005; Shaw et al., 2004; Hurley et al., 2005). Thr-172 can
also be phosphorylated by transforming growth factor-b
activated protein kinase-1 (TAK1) (Momcilovic et al., 2006;
Herrero-Martı´n et al., 2009), although the exact physiological
significance of that mechanism remains uncertain.
The discovery of LKB1 as an upstream kinase was particularly
interesting because LKB1 had previously been identified as the
product of a tumor suppressor gene (Alessi et al., 2006), and
AMPK was its first downstream target to be identified. It was
subsequently discovered that, in addition to the a1 and a2
subunits of AMPK, LKB1 also phosphorylates and activates 12
other enzymes with kinase domains closely related to those of
AMPK, now known as the AMPK-related kinase or ARK family
(Lizcano et al., 2004). LKB1 is only active in the form of a com-
plex with two other subunits, STRAD and MO25 (Hawley et al.,
2003). This complex appears to be constitutively active (Saka-
moto et al., 2004), with Thr-172 phosphorylation normally being
regulated instead by binding of ligands to the substrate, AMPK
(see below). By contrast, CaMKKb appears to have a very low
basal activity against AMPK in intact cells and only phosphory-
lates Thr-172 in response to treatments that increase intracel-
lular Ca2+ (Hawley et al., 2005; Hurley et al., 2005; Woods
et al., 2005).
The identities of the protein phosphatase(s) dephosphorylat-
ing Thr-172 are not fully resolved, although there is genetic
evidence in S. cerevisiae that there are two phosphatases
dephosphorylating this site. One is a complex between Glc7Chemistry & Biolog(the single PP1 catalytic subunit) and its targeting subunit Reg1
(Sanz et al., 2000), whereas the other is Sit4, the ortholog of
the mammalian phosphatase PP6 (Ruiz et al., 2011, 2012). In
MIN6 cells (a mouse pancreatic b cell line) evidence from siRNA
knockdowns suggests that a complex between PP1 and the tar-
geting subunit PPP1R6 dephosphorylates Thr-172 and, despite
no clear sequence relationship, DNA-encoding PPP1R6 com-
plements a reg1 mutant yeast strain (Garcia-Haro et al., 2010).
It has also been reported that RNAi-based depletion of PPM1E
(a member of the PPM family of protein phosphatases,
which are not related to the PPP family containing PP1 and
PP6) increases Thr-172 phosphorylation in HEK293 cells (Voss
et al., 2011).
The kinase domain (KD) of AMPK is immediately followed by
a small region termed the autoinhibitory domain (AID) (Figure 1).
It was given this name because truncated a subunits containing
the KD plus the AID have very low activity even when phosphor-
ylated on Thr-172, whereas constructs containing the KD alone
exhibit full activity (Go¨ransson et al., 2007; Pang et al., 2007;
Chen et al., 2009). In a crystal structure of a fission yeast KD-AID
construct, the AID forms a small domain with three a helices,
which interacts with the small and large lobes of the KD on
the opposite face to the active site, appearing to constrain the
kinase domain in a less active, ‘‘open’’ conformation. Mutations
in the predicted KD:AID interface in a heterotrimeric complex
from mammals also increased the basal activity in the absence
of AMP, suggesting that the AID is involved in the mechanism
of allosteric activation by AMP (Chen et al., 2009). However, in
the structure of an active mammalian heterotrimeric complex,
the AID appeared to be unstructured (Xiao et al., 2011), so its
role in the overall regulation of the AMPK heterotrimer remains
unclear.
TheC-terminal region of the a subunit (a-CTD) forms a globular
domain that interacts with the C-terminal domain of the b subunit
and is thus essential for formation of the abg complex (Crute
et al., 1998; Hudson et al., 2003; Xiao et al., 2007, 2011). The
KD/AID and the a-CTD are joined by a linker peptide of extended
conformation; in a recent structure (Xiao et al., 2011) this a-linker
wraps around the g subunit, rather like two arms stretching out
from the KD/AID and the a-CTD that hold the g subunit in a tight
embrace. The ‘‘clasped hands’’ of these arms are formed by
a structure called the ‘‘a hook,’’ which contacts one of the regu-
latory nucleotides bound to the g subunit (see below).
Several groups have reported that complexes containing the
a2 isoform are enriched in the nucleus in different cell types
(Salt et al., 1998; Turnley et al., 1999; Ai et al., 2002), although
a1 complexes do not appear to be completely excluded from
the nucleus. A short putative nuclear localization sequence
(KKIR, residues 224–227) has been highlighted toward the C
terminus of the a2 kinase domain (Suzuki et al., 2007); in a1
the equivalent sequence is KKIC. Interestingly, there are well-
defined and functional nuclear export sequences at the C
termini of both a1 and a2 (Kazgan et al., 2010). It seems likely
that both the a1 and a2 complexes shuttle in and out of the
nucleus, although this has not been studied in detail.
The b Subunits
The b1 and b2 subunits are encoded by two alternate genes in
mammals (PRKAB1 and PRKAB2 in humans). Both are widelyy 19, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1223
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rodent liver (Thornton et al., 1998). As already indicated, their
C-terminal domains (b-CTD) interact with the a-CTD, and the
b subunits then terminate with a short sequence that associates
with the g subunit via an inter-subunit b sheet (Amodeo et al.,
2007; Townley and Shapiro, 2007; Xiao et al., 2007, 2011). The
b-CTD thus forms the ‘‘core’’ of the heterotrimeric complex,
holding the a and g subunits together. Both b subunits are
subject to myristoylation at their N termini (Oakhill et al., 2010);
this is required for the ability of AMP and ADP binding to enhance
phosphorylation of Thr-172 (Oakhill et al., 2010, 2011). It has
also been proposed that myristoylation affects the translocation
of AMPK complexes containing a2 between the cytoplasm and
the nucleus (Suzuki et al., 2007).
Along with the b-CTD, the other b subunit region that is well
conserved between species is the central carbohydrate-binding
module (CBM, Figure 1), originally termed the glycogen-binding
domain (Hudson et al., 2003; Polekhina et al., 2003). This module
is related to CBMs found in other proteins, where they are often
fused to catalytic domains involved in the metabolism of
glycogen and starch and thus colocalize the catalytic domains
with their polysaccharide substrates (Machovic and Janecek,
2006). Although theCBMwasmissing from two partial structures
of the mammalian heterotrimer (Xiao et al., 2007, 2011), it was
present in a structure from budding yeast (Amodeo et al.,
2007). The CBM from rat b1 has also been crystallized on its
own, and conserved residues involved in carbohydrate binding
have been identified (Polekhina et al., 2005). The CBM of b2
hasahigher affinity for glycogen than that ofb1 (Koayet al., 2010).
Although it is clear that the b subunit CBMs cause AMPK
complexes to bind to the surface of glycogen particles (Hudson
et al., 2003; Polekhina et al., 2003; Bendayan et al., 2009), the
physiological role of this is not completely resolved. However,
glycogen synthase (GS), the key enzyme of glycogen synthesis
that is also bound to the glycogen particle, is a substrate for
AMPK. Both the muscle and liver isoforms of glycogen synthase
are phosphorylated by AMPK at N-terminal sites that cause
their inactivation (Carling and Hardie, 1989; Jørgensen et al.,
2004; Bultot et al., 2012), suggesting that one function of the
CBM is to colocalize AMPK with this downstream target.
Glycogen and synthetic oligosaccharides based on the struc-
ture of glycogen also inhibit AMPK, although inhibition by
glycogen varies with different preparations of the polysaccharide
(McBride et al., 2009). One hypothesis is that AMPK acts as
a glycogen sensor that regulates glycogen synthesis according
to certain aspects of glycogen structure, although the latter are
not yet well defined.
The g Subunits
The g1, g2, and g3 subunit isoforms are encoded by three alter-
nate genes in mammals (PRKAG1-3 in humans). The g1 isoform
appears to be expressed ubiquitously, whereas g2 and g3 are
most abundant in muscle. The g2 and g3 isoforms contain
N-terminal extensions that are unrelated to each other and are
not present in g1 (Figure 1); in both cases these extensions
can also occur as ‘‘long’’ and ‘‘short’’ forms because of the
use of alternate transcriptional start sites (Lang et al., 2000;
Yu et al., 2004). Recently, a third g2 variant (g2-3B) has been
identified that lacks the amino acids encoded by exons 1–3 in
the ‘‘long’’ form but has 32 unique residues encoded by an1224 Chemistry & Biology 19, October 26, 2012 ª2012 Elsevier Ltd Aalternate exon, 3B (Pinter et al., 2012). Both at the mRNA and
the protein level, g2 is expressed in adults in both cardiac and
skeletal muscle, whereas g3 appears to be restricted to skeletal
muscle (Cheung et al., 2000; Milan et al., 2000; Yu et al., 2004).
However, AMPK activity has been immunoprecipitated from
other tissues, such as brain, using an anti-g3 antibody (Cheung
et al., 2000). Both g3 and g2-3B are also expressed in fetal
mouse heart, and g2-3B appears to account for almost half of
total g2 protein in adult mouse heart (Pinter et al., 2012).
All three g subunit isoforms contain at their C termini four
tandem repeats of a sequence known as a cystathione b-syn-
thase (CBS) repeat; these are numbered CBS1-4 from the N
terminus to the C terminus (Figure 1). CBS1 is immediately
preceded by a short sequence involved in the interaction with
the b subunit (Viana et al., 2007; Xiao et al., 2007). CBS repeats
occur in around 20 other proteins in the human genome, invari-
ably as tandem pairs. Single tandem pairs form structures
known as Bateman domains, which are regulatory domains
that bind adenosine-containing ligands, either AMP, ADP, ATP,
or, in the case of cystathione b-synthase itself, S-adenosyl
methionine (Scott et al., 2004). The g subunits of AMPK are
unusual in having four rather than two repeats, and these form
two Bateman domains that assemble in a head-to-head manner
(Amodeo et al., 2007; Townley and Shapiro, 2007; Xiao et al.,
2007). Because of the 4-fold symmetry, there are four clefts
that could potentially bind adenine nucleotides; these are
numbered according to the number of the CBS repeat bearing
an aspartate residue that interacts with the nucleotide ribose
ring. Site 2 is unoccupied (CBS2 lacks an aspartate), whereas
site 4 contains AMP that is very tightly bound and nonexchange-
able and which may play a structural role. Sites 1 and 3 are the
sites at which AMP, ADP, and ATP bind reversibly in competi-
tion with each other. They bind AMP, ADP, and ATP with quite
similar affinity, although site 1 appears to have a higher affinity
for all three nucleotides (Scott et al., 2004; Xiao et al., 2011).
Canonical Regulation of AMPK by Adenine Nucleotides
and Calcium Ions
When cells are under metabolic stress (e.g., because of shortage
of glucose or oxygen) or are treated with a pharmacological
agent that inhibits ATP synthesis (e.g., almost any mitochondrial
inhibitor) or are under stress because of accelerated ATP
consumption (e.g., because of activation of motor proteins
during muscle contraction), there will be an increase in the
cellular ADP:ATP ratio. In unstressed cells the concentration of
AMP is usually very low because the high ATP:ADP ratio drives
the adenylate kinase reaction (ATP + AMP 4 2ADP) toward
ADP synthesis. However, whenever the ADP:ATP ratio rises
during energetic stress, the highly reversible adenylate kinase
reaction will be partially displaced toward synthesis of AMP,
causing a large rise in AMP. Increases in ADP and AMP (relative
to ATP) are thus signals that cells are under energetic stress,
and are the key signals that switch on AMPK in its canonical,
energy-sensing role. In unstressed cells, the two exchangeable
sites on the g subunit (sites 1 and 3) are probably occupied
by ATP. During a mild stress both ADP:ATP and AMP:ATP ratios
will rise, but because AMP concentrations will still be low
compared with ATP and ADP, it is most likely ADP that initially
displaces ATP. The majority of cellular ATP is present asll rights reserved
Figure 2. Acute Metabolic Effects of AMPK Activation
Upward/downward arrows indicate that the target protein (inner wheel) or
pathway (outer wheel) are activated/inactivated. See text for numbering and
key to acronyms. Green arrows on the ‘‘spokes’’ of the wheel indicate acti-
vation, red lines with a bar at the end indicate inhibition, and black arrows and
‘‘??’’ indicate that the direct target protein that explains the effect, is not known.
Figure 3. Effects of AMPK Activation on Transcription
Upward/downward arrows indicate that the target transcription factor or co-
activator (inner wheel) or target genes (outer wheel) are activated/inactivated.
Note that SIRT1 (on spoke 5) deactylates both FOXO family transcription
factors and the transcriptional coactivator PGC-1a.
Chemistry & Biology
Reviewa complex in which the b and g phosphates bind a Mg2+ ion
(Mg.ATP2), which has a lower affinity for the g subunit than
free ATP4 (Xiao et al., 2011). Thus, when binding to the
AMPK-g subunits ADP does not have to compete with total
ATP but only with the less abundant ATP4. Given its low
concentration during a mild stress, AMP may only displace
ADP or ATP as stress becomes more severe and its concen-
tration rises further.
Binding of ADP or AMP causes a conformational change in
the AMPK complex that both promotes phosphorylation of
Thr-172 (Hawley et al., 1995; Oakhill et al., 2011) and inhibits
dephosphorylation (Davies et al., 1995; Suter et al., 2006; Xiao
et al., 2011). Complete phosphorylation can cause >100-fold
activation, although the degree of phosphorylation may never
come close to this in vivo. It is important to note that ADP and
AMP appear to affect phosphorylation and dephosphorylation
entirely by binding to AMPK, rather than by regulating the
upstream kinase or phosphatase. The effect of phosphorylation
is further amplified by allosteric activation, which is triggered
only by binding of AMP, not ADP. It has been proposed (Xiao
et al., 2011) that the allosteric effect is due to binding of AMP
to the high affinity site (site 1), whereas the effect on phosphor-
ylation state is mediated by binding of ADP or AMP to the lower
affinity site (site 3). However, mutations of the aspartate residues
that bind the nucleotide ribose rings in sites 1 and 3, and even
the nonexchangeable site (site 4), have been found to reduce
both responses (Oakhill et al., 2011). Thus, there appear to be
complex, co-operative interactions between the nucleotides
bound at these three sites, which are not yet fully understood.
It has also been proposed that protection against Thr-172
dephosphorylation is mediated by the ‘‘a hook’’ region of the
a subunit; a structure of a complex with AMP bound at site 3
suggests that the a hook would be able to interact with AMPChemistry & Biologor ADP at this site but that the extra phosphate on ATP might
prevent this interaction (Xiao et al., 2011).
The other ‘‘canonical’’ activation mechanism involves the
phosphorylation of Thr-172 by CaMKKb in response to a rise in
intracellular Ca2+. This occurs, for example, in response to depo-
larization of neurons (Hawley et al., 2005), activation of receptors
coupled to phosphatidylinositol-specific phospholipases, and
hence Ca2+ release, in various cell types (Stahmann et al.,
2006; Thornton et al., 2008; Yang et al., 2011), and activation
of the antigen receptor in T lymphocytes (Tama´s et al., 2006).
This mechanism can occur in the absence of any change in
cellular nucleotides, although the two canonical mechanisms
(AMP/ADP andCa2+) can also synergize with each other (Fogarty
et al., 2010).
Downstream Targets and Use of AMPK Activators
in Diabetes and Cancer
AMPK phosphorylates serine residues surrounded by a well-
defined recognition motif (Scott et al., 2002; Gwinn et al.,
2008). Space constraints do not permit a comprehensive dis-
cussion of the entire literature on downstream targets, and the
reader is referred to other recent reviews (Hardie, 2007, 2011;
Steinberg and Kemp, 2009; Mihaylova and Shaw, 2011; Hardie
et al., 2012). However, Figures 2, 3, and 4 summarize some
well-characterized targets that are also briefly discussed below,
with one or two representative references provided in each case.
Figure 2 involves targets involved in the acute regulation of
metabolism. Progressing clockwise around the spokes of the
‘‘wheel,’’ starting at 12 o’clock:
(1) AMPK activates GLUT4-mediated glucose uptake in
muscle via phosphorylation of TBC1D1 (Frøsig et al.,
2010), a Rab-GAP protein that, under basal conditions,
inhibits fusion of intracellular GLUT4-containing vesiclesy 19, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1225
Figure 4. Effects of AMPK Activation Other than on Metabolism
and/or Transcription
Upward/downward arrows indicate that the functions of the target protein
(inner wheel) or target process (outer wheel) are activated/inactivated.
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triggers 14-3-3 binding, causing TBC1D1 to dissociate
from the intracellular vesicles;
(2) AMPK also activates glucose uptake in other cells by acti-
vation of GLUT1 already present on the membrane
(Barnes et al., 2002). However, GLUT1 does not appear
to be a direct target for AMPK, and the molecular mecha-
nism remains unknown;
(3) AMPK activates glycolysis in cardiac myocytes by phos-
phorylation and activation of the PFKFB2 isoform of
6-phosphofructo-2-kinase, which catalyzes the synthesis
of fructose-2,6-bisphosphate, a key activator of the
glycolytic enzyme 6-phosphofructo-1-kinase (Marsin
et al., 2000);
(4) AMPK also activates glycolysis in monocytes and macro-
phages by phosphorylation and activation of the PFKFB3
isoform of 6-phosphofructo-2-kinase. This may allow
macrophages to generate ATP efficiently in regions of
infection or injury that are hypoxic (Marsin et al., 2002).
(5) AMPK activates fatty acid uptake via translocation of the
transporter CD36 to the plasma membrane, although the
molecular mechanism remains unknown (Habets et al.,
2009);
(6) AMPK activates fatty acid oxidation by phosphorylating
and inactivating the mitochondria-associated isoform of
acetyl-CoA carboxylase (ACC2), thus lowering malonyl-
CoA, an inhibitor of fatty acid uptake into mitochondria
via the carnitine:palmityl-CoA transferase system (Merrill
et al., 1997);
(7) Lipolysis (hydrolysis of triglyceride stores) in adipose
tissue is catalyzed by desnutrin/ATGL, which removes
the first fatty acid, and hormone-sensitive lipase (HSL),
which removes the second (Zimmermann et al., 2004).
AMPK inhibits lipolysis in rodent and human adipocytes
by phosphorylation of HSL, antagonizing its activation
by cyclic AMP-dependent protein kinase and its translo-6 Chemistry & Biology 19, October 26, 2012 ª2012 Elsevier Ltd Acation to the surface of the lipid droplet (Garton et al.,
1989; Daval et al., 2005; Bourron et al., 2010). Because
lipolysis is a catabolic pathway, it might seem illogical
that AMPK should inhibit it. However, this may be amech-
anism to limit the production during lipolysis of free fatty
acids; if these are allowed to accumulate they recycle
into triglycerides, creating a futile cycle that consumes
ATP. Consistent with this, AMPK is activated in 3T3-L1
adipocytes by cyclic AMP-elevating agents, and this is
associated with increases in cellular AMP:ATP ratios,
but both effects are blunted by inhibition of lipolysis or
of the acyl-CoA synthetase required for recycling of
fatty acids back to triglycerides (Gauthier et al., 2008).
Somewhat paradoxically, AMPK has been reported to
phosphorylate and activate desnutrin/ATGL in mamma-
lian cells (Ahmadian et al., 2011), although in nematode
worms the enzyme appears to be inhibited by AMPK
phosphorylation (Narbonne and Roy, 2009), which is
more consistent with the known effects of AMPK on
HSL function in mammals;
(8) AMPK inhibits fatty acid synthesis by directly phosphory-
lating and inactivating the cytosolic isoform of acetyl-CoA
carboxylase (ACC1) (Davies et al., 1992); phosphospecific
antibodies that recognize the key phosphorylation sites
on both ACC1 and ACC2 are widely used as markers for
AMPK activation.
(9) AMPK inhibits triglyceride and phospholipid synthesis
by causing inactivation of the first enzyme involved in
their synthesis, glycerol phosphate acyl transferase
(GPAT); it remains unclear whether GPAT is a direct
substrate for AMPK (Muoio et al., 1999);
(10) AMPK inhibits isoprenoid/cholesterol synthesis by
direct phosphorylation and inactivation of 3-hydroxy-
3-methylglutaryl CoA reductase (HMGR) (Clarke and
Hardie, 1990);
(11) AMPK inhibits muscle glycogen synthesis by phos-
phorylation and inactivation of glycogen synthase-1
(Jørgensen et al., 2004);
(12) AMPK inhibits liver glycogen synthesis by phosphoryla-
tion and inactivation of glycogen synthase-2 (Bultot
et al., 2012);
(13) AMPK inhibits protein synthesis by phosphorylating
tuberous sclerosis complex protein-2 (TSC2), causing
Rheb (a small G protein that activates mammalian
target-of-rapamycin complex-1, mTORC1) to be con-
verted to its inactive GDP-bound form (Inoki et al.,
2003); and
(14) AMPK also inhibits protein synthesis by directly phos-
phorylating Raptor, a subunit of the mTORC1 complex
(Gwinn et al., 2008).
In addition to these acute effects on metabolism, AMPK also
has numerous effects on transcription, which are summarized
in Figure 3. Progressing clockwise around the spokes of the
wheel, starting at 12 o’clock:
(1) AMPK phosphorylates cyclic AMP response element
binding protein (CREB)-regulated transcription coactiva-
tor-2 (CRTC2, formerly called TORC2), causing it to bindll rights reserved
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hibiting activation of genes encoding gluconeogenic
enzymes in the liver (Koo et al., 2005);
(2) AMPK phosphorylates class IIa lysine deacetylases
(HDAC-4, 5 and 7), causing them to bind 14-3-3 pro-
teins that retain them in the cytoplasm and preventing
formation of heterodimers with class I lysine deacetylases
(e.g., HDAC3). The latter activate transcription of specific
genes, including gluconeogenic genes, and this therefore
represents a second mechanism (see 1 above) by which
AMPK downregulates gluconeogenesis (Mihaylova et al.,
2011);
(3) AMPK phosphorylates sterol response element binding
protein-1c (SREBP-1c), preventing its proteolytic pro-
cessing and nuclear translocation and thus inhibiting
transcription of lipogenic genes, including those encod-
ing ACC-1 and fatty acid synthase (Li et al., 2011);
(4) AMPK phosphorylates carbohydrate response element
binding protein (ChREBP), inhibiting its DNA binding and
consequent activation of transcription of lipogenic genes,
including the liver isoform of pyruvate kinase (Kawaguchi
et al., 2002);
(5) AMPK activates the class III deacetylase SIRT1, which
deacetylates FOXO-1 and 3, activating genes modu-
lated by those transcription factors (see 7 below). SIRT1
also deacetylates and activates PGC-1a (see 6 below).
The mechanism by which AMPK activates SIRT1 remains
uncertain, although it has been proposed that effects of
AMPK on metabolism increase the cellular concentration
of NAD+, a cosubstrate of SIRT1 (Canto´ et al., 2009);
(6) AMPK activation causes phosphorylation of peroxisome
proliferator-activated receptor-g (PPARg) coactivator-1a
(PGC-1a), a ‘‘master regulator’’ of expression of mito-
chondrial genes that triggers mitochondrial biogenesis.
The phosphorylation sites identified do not closely
conform to the AMPK recognition motif so this may
not be a direct effect, but this phosphorylation is
believed to activate transcription of PGC-1a by a posi-
tive feedback loop acting on its own promoter (Ja¨ger
et al., 2007). In addition, PGC-1a is deacetylated and
activated by SIRT1 in response to AMPK activation
(see 5 above);
(7) AMPK directly phosphorylates several sites on the tran-
scription factor FOXO3 (see also 5 above), activating
transcription of many genes, including genes involved
in resistance to oxidative stress (Greer et al., 2007);
(8) AMPK phosphorylates the transcriptional coactivator
p300, reducing its interaction with, and thus inhibiting
transcription induced by, nuclear hormone receptors,
such as PPAR-g, and the thyroid hormone receptor
(Yang et al., 2001);
(9) AMPK activation induces transcription from genes modu-
lated by the constitutive androstane receptor (CAR),
particularly those (e.g., CYP2B6) encoding cytochrome
P450 enzymes that metabolize xenobiotic compounds,
such as phenobarbital (Rencurel et al., 2005); and
(10) AMPK phosphorylates the cryptochrome protein
Cry1, triggering its degradation and thus relieving its
inhibitory effects on the BMAL1:CLOCK heterodimer,Chemistry & Biologa transcription factor involved in the establishment of
circadian rhythms of gene expression (Lamia et al.,
2009).
In addition to the effects on expression of messenger RNAs
described above, AMPK phosphorylates the RNA polymerase I
transcription factor TIF-1A, thus inhibiting the production of
ribosomal RNA (Hoppe et al., 2009). In proliferating cells, rRNA
accounts for around 80%–90% of all RNA synthesis, so this
mechanism would conserve ATP, while also inhibiting cell
growth under conditions of energy limitation.
Figure 4 summarizes regulation by AMPK of some targets
involved in cellular processes other than metabolism or tran-
scription. Progressing clockwise around the spokes of the
wheel, starting at 12 o’clock:
(1) AMPK activation triggers phosphorylation of p53 at
Ser-15 (human sequence numbering). This site does not
fit the AMPK recognition motif, so this may not be a
direct phosphorylation, but it causes p53 stabilization
and thus activates transcription of p21WAF1, a cyclin-
dependent kinase inhibitor that triggers G1:S phase cell-
cycle arrest (Imamura et al., 2001; Jones et al., 2005);
(2) AMPK activation causes phosphorylation of another
cyclin-dependent kinase inhibitor, p27KIP1, at a C-terminal
threonine residue; this site does not fit the AMPK
consensus motif, so this may not be a direct phosphory-
lation. However, it causes p27KIP1 stabilization, inducing
G1:S phase cell cycle arrest and autophagy (Liang et al.,
2007);
(3) AMPK phosphorylates PPP1R12C, a regulatory subunit
of protein phosphatase-1 (PP1) that targets PP1 to
dephosphorylate myosin regulatory light chain (MRLC).
Phosphorylation triggers binding of 14-3-3 proteins to
PPP1R12C, and this may prevent the phosphatase
complex from dephosphorylating MRLC. Phosphoryla-
tion of PPP1R12C appears to be necessary for com-
pletion of mitosis, as discussed further under (4) below
(Banko et al., 2011);
(4) AMPK also phosphorylates PAK2, a protein kinase that
phosphorylates MRLC at the N-terminal site that is
dephosphorylated by the PPP1R12C:PP1 complex;
phosphorylation of MRLC activates the ATPase activity
of nonmuscle myosin, triggering the movement of this
motor protein along actin fibers. Although it is not yet clear
whether phosphorylation by AMPK regulates PAK2
activity, MRLC phosphorylation is required for completion
of mitosis (Banko et al., 2011). This helps to explain
defects in chromosomal segregation observed in
Drosophila larvae that lack AMPK (Lee et al., 2007) and
is consistent with findings that AMPK is found to be
phosphorylated at the mitotic apparatus in M phase cells
(Vazquez-Martin et al., 2011). Although mitosis is an
energy-requiring event and it might appear paradoxical
that AMPK should activate it, it may be crucial for cells
undergoing mitosis to complete the process if energy
stress occurs while it is happening so that they can arrest
in a more orderly manner in the following G1 phase
instead;y 19, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1227
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autophagy. Autophagy is critical to recycle amino acids
and other components in cells starved of nutrients, while
autophagy of mitochondria (mitophagy) recycles compo-
nents from damaged mitochondria that are no longer
efficiently producing ATP (Egan et al., 2011);
(6) AMPK phosphorylates and inactivates the cystic fibrosis
transmembrane regulator (CFTR), a Cl channel gated
by ATP that is involved in trans-epithelial salt transport
(Hallows et al., 2003). Salt transport is an energy-requiring
process, so this would represent an energy-conserving
mechanism;
(7) AMPK phosphorylates the voltage-gated, delayed recti-
fier K+ channel, Kv2.1, in its C-terminal tail; phosphoryla-
tion sensitizes the channel so that it opens at lower
extents of membrane depolarization. This reduces
membrane excitability and the consequent firing of action
potentials in central neurons. Because firing of action
potentials in the brain is a major consumer of energy,
this mechanism may protect neurons during metabolic
stress (Ikematsu et al., 2011); and
(8) AMPK phosphorylates another voltage-gated K+ channel,
KCa1.1 (also known as BKCa); in this case the phosphory-
lation inactivates the channel. This is believed to be part
of the oxygen-sensing mechanism in type I cells of
the carotid body: hypoxia activates AMPK, causing
inactivation of KCa1.1 that then facilitates opening of
voltage-gated Ca2+ channels. Increases in cell Ca2+
cause neurotransmitter release from the type I cells, trig-
gering firing of the carotid sinus nerve that signals to the
brain, where corrective changes in breathing patterns
are initiated (Ross et al., 2011).
In summary, AMPK activation has numerous and complex
effects on cell function, although these can mostly be viewed
as mechanisms to restore cellular energy homeostasis when it
becomes disrupted. By direct phosphorylation of metabolic
enzymes and by effects on transcription, AMPK switches on
catabolic pathways, such as the uptake of glucose and fatty
acids, and their metabolism by mitochondrial oxidation and
(in the case of glucose) by glycolysis. In addition, AMPK switches
off biosynthetic pathways, such as the synthesis of glucose,
glycogen, and lipids in the liver. By promoting muscle glucose
uptake and metabolism and by inhibiting hepatic glucose
production, AMPK activation can explain the antihyperglycemic
actions of the drug metformin, which is used to treat type
2 diabetes and is discussed further below. In addition, type 2
diabetes is thought to be primarily caused by insulin resistance,
which is strongly associated with excess triglyceride storage in
liver and muscle. By switching off the synthesis of fatty acids
and triglycerides and enhancing fat oxidation instead, AMPK
activation might also explain the insulin-sensitizing actions of
metformin.
The synthesis of fatty acids, triglycerides, cholesterol, RNA
(especially rRNA), and proteins are all upregulated in rapidly
proliferating cells, such as tumor cells. AMPK activation
switches off all of these pathways and would therefore be ex-
pected to exert a cytostatic, antitumor effect, reinforced by its
ability to cause cell-cycle arrest. These effects of AMPK might1228 Chemistry & Biology 19, October 26, 2012 ª2012 Elsevier Ltd Aexplain, at least in part, the tumor suppressor effects of the
upstream kinase LKB1 (Alessi et al., 2006), as well as findings
that metformin usage reduces the risk of cancer in diabetics
(Evans et al., 2005) and that metformin and other AMPK activa-
tors (phenformin, A-769662, see below) delay the onset of
tumorigenesis in mouse models (Huang et al., 2008). However,
AMPK may represent a ‘‘double-edged sword’’ in cancer in
that, once a tumor has arisen, it might exert a cell-autonomous
effect to protect tumor cells against the actions of cytotoxic
agents. AMPK activators might therefore be deleterious in the
treatment (as opposed to the prevention) of cancer. Consistent
with this idea, in an siRNA screen of protein kinases whose
loss was synthetically lethal with c-Myc activation in U2OS cells,
two major hits obtained were AMPK-a1 and the AMPK-related
kinase ARK5 (NUAK1). These results suggest that these kinases
help to protect cells against the metabolic stresses caused by
c-Myc activation (Liu et al., 2012). Similarly, it has been sug-
gested that AMPK protects cells against the metabolic stress
caused by glucose deprivation and promotes anchorage-
independent growth and solid tumor formation in vivo, by
reducing NADPH consumption by lipid synthesis and thus
preserving the nucleotide for protection against oxidative stress
(Jeon et al., 2012).
Activation of AMPK by Drugs and Xenobiotics
In this section we review the mechanisms by which AMPK is
activated by pharmacologically active agents. Some of these
are drugs in clinical use in conventional medicine, whereas
others are natural products present in traditional medicines or
derived from food or beverages claimed to have ‘‘nutraceutical’’
properties. The majority of these were in use for these purposes
before it was realized that they were activators of AMPK. An
important tool in establishing their mechanisms of action was
a pair of isogenic cell lines derived from HEK293 cells, which
express AMPK complexes containing g2 with or without a single
substitution in site 3 (R531G) that renders the complex insensi-
tive to the effects of ADP and AMP on phosphorylation (Hawley
et al., 2010). The mutant cells will be referred to below as RG
cells. Agents that act by increasing cellular ADP or AMP fail to
activate AMPK in the RG cells, whereas agents that act by other
mechanisms (e.g., the Ca2+ ionophore A23187, which increases
intracellular Ca2+ and activates CaMKKb) activate AMPK in the
RG cells to the same extent as in the wild-type cells. Other
ancillary approaches used in this study were to measure
changes in ADP:ATP ratio by capillary electrophoresis of acid
extracts and the use of an extracellular flux analyzer to measure
oxygen uptake (Hawley et al., 2010).
5-Aminoimidazole-4-Carboxamide Riboside
5-Aminoimidazole-4-carboxamide riboside (AICA riboside) is an
adenosine analog taken up into cells by adenosine transporters
and phosphorylated by adenosine kinase to the equivalent
ribotide, ZMP (Figure 5), which mimics all three effects of AMP
on the AMPK complex (Corton et al., 1995). Because ZMP binds
to site 3 on the g subunit in a similar manner to AMP (Day et al.,
2007), AICA riboside does not activate AMPK in RG cells,
although, unlike AMPK activators inhibiting mitochondrial func-
tion, it does not cause changes in ADP:ATP ratio or oxygen
uptake (Hawley et al., 2010). Although ZMP is z50-fold less
potent as an activator than AMP, AICA riboside activatesll rights reserved
Figure 5. Structures of Some AMPK-
Activating Compounds and Related
Compounds
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concentrations within the cell (Corton et al., 1995). Because it is
effective in vivo (although it is not orally available and has to be
injected), AICA riboside has been much used to identify physio-
logical processes regulated by AMPK in animal models.
Another interesting feature of AICA riboside is that, under the
name ‘‘acadesine,’’ it was used in small-scale clinical trials in
humans undergoing coronary artery bypass graft surgery, where
it appeared to provide some benefit (Mangano, 1997). These
trials were undertaken before it was realized that AICA riboside
activated AMPK, and at the time it was viewed as a means to
rapidly replenish the total cellular adenine nucleotide content.
Another interesting point is that ZMP is a naturally occurring
intermediate in cellular purine nucleotide synthesis and ismetab-
olized by the enzyme AICAR transformylase, which catalyzes
the penultimate step in the synthesis of the purine nucleotide
IMP. AICA riboside tends to work better as an AMPK-activating
agent in quiescent, primary cells than in rapidly proliferating
cells, possibly because the latter have a higher rate of purine
synthesis, so they more rapidly metabolize ZMP. Consistent
with this, the anticancer agent methotrexate (an antifolate drug
that inhibits AICAR transformylase) sensitizes tumor cells to
the AMPK-activating and growth-inhibitory effects of AICA
riboside (Beckers et al., 2006). Pemetrexed, another antifolate
drug used in the treatment of lung cancer, is a more selective
inhibitor of AICAR transformylase, and it can cause accumula-Chemistry & Biology 19, October 26, 2012 ªtion of ZMP and activation of AMPK
even in the absence of exogenous AICA
riboside (Racanelli et al., 2009). These
findings raise the possibility that some
effects of antifolate drugs used to treat
cancer might be mediated by AMPK.
Metformin, Phenformin, and
Galegine
Metformin is currently the first choice
drug for treatment of type 2 diabetes.
Because of the very high prevalence of
this disorder, it is currently prescribed
to more than 100 million people, or more
than 1% of the world population. Metfor-
min is derived from guanidine which,
along with galegine (Figure 5), is a natural
product found in the plant Galega
officinalis (also known as Goat’s Rue).
Goat’s Rue was described in the 18th
century as an herbal medicine to treat
‘‘symptoms such as thirst and frequent
urination’’ (Hill, 1772). Interestingly, it is
classed as a noxious weed in the United
States because it is poisonous to herbi-
vores, which presumably includes goats!
Guanidine is quite toxic, but galegine(an isoprenyl derivative) is a potent AMPK activator (Mooney
et al., 2008) and was tested for treatment of diabetes in humans,
with some success, in the 1920s (Muller and Reinwein, 1927).
Metformin (dimethylbiguanide) is a biguanide derivative that
was synthesized in the 1920s and found to be effective in
lowering blood glucose in animals (Hesse and Taubmann,
1929). However, the success of insulin as a therapy for diabetes,
developed in the same decade, put further studies of the bigua-
nide drugs on hold. Metformin and its sister drug, phenformin
(phenethylbiguanide, Figure 5), were finally introduced into
clinical practice in the 1960s, by which time the distinction
between type 1 and type 2 diabetes had beenmade. Phenformin
was withdrawn from the US market in 1978 due to a rare but life-
threatening side effect of lactic acidosis, but use of metformin
has greatly increased, particularly when impressive results
were reported in the UK Prospective Diabetes Study (UK
Prospective Diabetes Study (UKPDS) Group, 1998).
Although the major effect of metformin was known to be
a reduction of the high hepatic glucose production in type 2
diabetics (Hundal et al., 2000), its molecular mechanism re-
mained obscure until it was reported that it activated AMPK
in isolated hepatocytes (Zhou et al., 2001). The drug did not,
however, activate AMPK or affect its phosphorylation by
upstream kinases and phosphatases in cell-free systems (Haw-
ley et al., 2002), suggesting that it acted indirectly. Metformin
inhibits Complex I of the respiratory chain (El-Mir et al., 2000;2012 Elsevier Ltd All rights reserved 1229
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inhibiting ATP synthesis and thus increasing cellular ADP and
AMP. This was confirmed when it was found that RG cells
were completely resistant to the effects of metformin to activate
AMPK; the same was observed for phenformin and galegine. As
expected from this mechanism, all three agents also increased
the cellular ADP:ATP ratio and inhibited oxygen uptake (Hawley
et al., 2010). There remains some controversy as to the extent to
which the therapeutic actions of metformin are mediated by
AMPK. In favor of this idea, micewith a conditional liver knockout
of LKB1, where liver AMPK is no longer activated by metformin,
failed to display the antihyperglycemic effects of metformin
(Shaw et al., 2005). However, mice with a conditional liver
knockout of both AMPK catalytic subunits (a1 and a2) still
displayed some responses to metformin in vivo, and acute
inhibition of glucose production by metformin in hepatocytes
isolated from the mice was still observed (Foretz et al., 2010).
A potential explanation of the latter effect is that fructose-1,6-
bisphosphatase, one of the key enzymes of gluconeogenesis,
is inhibited by AMP. By inhibiting mitochondrial respiration
and increasing AMP and ADP, metformin could clearly also
modulate AMP- or ADP-sensitive enzymes other than AMPK,
such as fructose-1,6-bisphosphatase.
Thiazolidinediones
Representatives of another major class of anti-diabetic drug, the
thiazolidinediones, including rosiglitazone (Fryer et al., 2002),
pioglitazone (Saha et al., 2004) and troglitazone (LeBrasseur
et al., 2006), also activate AMPK in intact cells. Although thiazo-
lidinediones have a known direct target, i.e., the transcription
factor PPAR-g, activation of AMPK in mammalian tissues
appears to be too rapid to be explained by effects on transcrip-
tion (LeBrasseur et al., 2006). One major effect of thiazolidine-
diones, in this case acting via PPAR-g, is thought to be the induc-
tion and release of the insulin-sensitizing hormone, adiponectin,
from adipocytes. Consistent with this, markers of insulin resis-
tance were improved by treatment with pioglitazone (10 mg/kg)
in genetically obese, leptin-deficient (ob/ob) mice, but this
effect was lost if the adiponectin gene was also knocked out
(Kubota et al., 2006). Interestingly, however, some amelioration
of disease markers was still seen in the adiponectin null mice
at slightly higher doses of pioglitazone (30 mg/kg) (Kubota
et al., 2006); it is tempting to speculate that this adiponectin-
independent effect wasmediated by cell-autonomous activation
of AMPK. In any case, the insulin-sensitizing effects of adiponec-
tin are most likely mediated by the ability of the hormone to
activate AMPK and stimulate fat oxidation in liver and muscle
(Yamauchi et al., 2002). Thus, thiazolidinediones activate
AMPK both by a humoral, adiponectin-dependent mechanism
and by a cell-autonomous, adiponectin-independent mecha-
nism. It is also clear that the latter is caused (like the effect of
metformin) by inhibition of Complex I of the respiratory chain
(Brunmair et al., 2004). Thus, thiazolidinediones fail to activate
AMPK in RG cells, increase the cellular ADP:ATP ratio, and
inhibit oxygen uptake (Fryer et al., 2002; Hawley et al., 2010).
2-Deoxyglucose
2-Deoxyglucose (2DG) is taken up into cells by glucose trans-
porters and converted by hexokinase to 2-deoxyglucose-6-
phosphate, which is not metabolized by glycolysis beyond that
point. Although usually described as an inhibitor of glycolysis,1230 Chemistry & Biology 19, October 26, 2012 ª2012 Elsevier Ltd Ait may activate AMPK in part by depleting ATP due to its rapid
and uncontrolled phosphorylation by hexokinase. As expected
from this mechanism, 2DG caused increases in ADP:ATP and
failed to activate AMPK in RG cells, although unlike AMPK
activators acting on mitochondrial function it did not inhibit
oxygen uptake (Hawley et al., 2010). Interestingly, 2DG can be
metabolized to some extent by the pentose phosphate pathway,
and it has recently been suggested that the generation of
NADPH by this route could represent an AMPK-independent
mechanism by which 2DG protects cells against the effects of
glucose deprivation (Jeon et al., 2012).
A-769662 and Salicylate
Given that AMPK is an attractive target for drugs aimed at type 2
diabetes, it is not surprising that pharmaceutical companies
have conducted high-throughput screens using their compound
libraries. Abbott Laboratories developed a thienopyridone
compound, A-769662 (Figure 5), which caused allosteric acti-
vation of purified AMPK in cell-free assays. Although the oral
availability of this compound is poor, when injected intraperito-
neally it had metabolic effects expected for an AMPK activator,
that is, increased fat oxidation in normal rats and reduced
weight gain, decreased plasma glucose and triglycerides, and
decreased liver triglycerides in obese (ob/ob) mice (Cool et al.,
2006). Interestingly, A-769662 mimics at least two of the effects
of AMP on the AMPK system, that is, allosteric activation and
protection against Thr-172 dephosphorylation, yet it is clear
that it binds at different site(s). Thus, it did not displace [3H]
AMP from the AMPK-g2 subunit in a scintillation proximity assay
(Go¨ransson et al., 2007), and did not activate AMPK complexes
containing the b2 subunit (Scott et al., 2008), or complexes in
which the b1 subunit carried an S108A mutation (Sanders
et al., 2007), both of which remain fully sensitive to activation
by AMP. Moreover, A-769662 still activates AMPK in RG cells,
unlike agents that increase AMP and ADP (Hawley et al., 2010,
2012).
Why should the AMPK complex have a distinct binding site
for A-769662, a purely synthetic molecule? It seemed likely there
is a natural ligand that binds at that site, and one such natural
ligand is salicylate (Figure 5). Salicylate was traditionally ex-
tracted from willow bark (Stone, 1763), although it is in fact
produced by many plants as a hormone used in a defense
response triggered by infection by fungi and other pathogens
(Reymond and Farmer, 1998). Acetyl salicylate (ASA, trade
name aspirin) is a derivative that is easier to take orally than
salicylate, although it is rapidly broken down to salicylate once
it enters the circulation (Higgs et al., 1987). Whereas cyclo-oxy-
genases (COX1 and COX2) are the established targets for
aspirin, it has been reported recently that salicylate (although
not aspirin) is a direct activator of AMPK at concentrations that
are reached in human plasma after oral treatment with high-
dose aspirin (Hawley et al., 2012). Although a much smaller
molecule and a less potent activator of AMPK than A-769662,
salicylate shows some structural resemblance to it (Figure 5). It
is clear that salicylate binds at a site that overlaps with that
used by A-769662, because (1) both compounds cause allo-
steric activation, with salicylate antagonizing the larger effect
of A-769662, and (2) effects of both compounds are greatly
reduced in AMPK complexes containing the b2 rather than the
b1 isoform and are blocked by an S108A mutation in b1 (Hawleyll rights reserved
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that are mediated by AMPK, because administration of either
compound to mice led to an enhanced switch to fat oxida-
tion on withdrawal of food, effects that were abolished in b1
knockout mice (Hawley et al., 2012). Although salicylate is not
directly synthesized by humans, it has probably been a com-
ponent of the diet since humans evolved, especially since at
one time humans might have often eaten moldy vegetable
matter. It is tempting to speculate that some of the apparent
protection against cancer provided by regular aspirin use (Roth-
well et al., 2012a, 2012b) might be mediated by AMPK.
Phenobarbital
Phenobarbital is another drug that was in clinical use long before
it was known to activate AMPK. It is a particularly effective
inducer of cytochrome P450 enzymes that catalyze oxidation
of hydrophobic drugs, a key initial step in the process that
renders them more water soluble for excretion. The gene
CYP2B6, encoding one cytochrome P450 in humans, is induced
by the nuclear hormone receptor CAR (constitutive androstane
receptor). It has been reported that phenobarbital activates
AMPK and that other AMPK activators (AICA riboside, metfor-
min) also induce CYP2B6 in a human hepatoma cell line,
whereas in hepatocytes from AMPK null mice phenobarbital
failed to induce Cyp2b10, the mouse ortholog (Rencurel et al.,
2005, 2006). Thus, induction of this P450 enzyme by phenobar-
bital is mediated by AMPK activation. Experiments with wild-
type and RG mutant HEK293 cells confirmed that phenobarbital
activates AMPK, like biguanides and thiazolidinediones,
because it is an inhibitor of the respiratory chain (Hawley et al.,
2010). Mitochondria contain several very large multiprotein
complexes, including the four respiratory chain complexes as
well as the ATP synthase. It seems likely that there might be
many binding sites within these complexes where hydrophobic,
xenobiotic compounds could bind and cause some inhibition
of ATP production. An interesting speculation is that AMPK is
being used in this case as a general sensor of mitochondrial
poisons that might need to be eliminated by cytochrome P450
metabolism.
Nutraceuticals and Traditional Medicines
Over recent years, a bewildering variety of natural plant prod-
ucts, some of which are present in foods and beverages used
by humans, have been reported to activate AMPK in intact cells.
Many of these are reputed to have health benefits and are being
touted as ‘‘nutraceuticals.’’ Equally, there have been several
reports of AMPK activation by plant products that are compo-
nents of traditional medicines. As well as galegine and salicylate
(discussed above), these plant products include resveratrol
from grapes and red wine (Baur et al., 2006), epigallocatechin-
3-gallate from green tea and capsaicin from Chili peppers
(Hwang et al., 2005), curcumin from turmeric (Lim et al., 2009),
and garlic oil from Allium sativum (Ki et al., 2007), as well as
two compounds derived from traditional Chinese medicine,
berberine from Chinese Goldthread (Turner et al., 2008) and
hispidulin from Snow Lotus (Lin et al., 2010). Although some of
these can be classed as polyphenols, they have very varied
structures and it was at first difficult to see how they could all
be AMPK activators. However, it has now been shown that
several inhibit mitochondrial function, either inhibiting the
respiratory chain (berberine; Turner et al., 2008) or the F1 ATPChemistry & Biologsynthase (resveratrol and EGCG; Zheng and Ramirez, 2000), or
acting as uncouplers (curcumin; Lim et al., 2009). Consistent
with the idea that this is how they activate AMPK, berberine
and resveratrol decreased the ATP:ADP ratio in cultured cells
and failed to activate AMPK in cells expressing the AMP/ADP-
insensitive RG mutant (Hawley et al., 2010).
Why should so many plants produce compounds that are
mitochondrial inhibitors and hence AMPK activators? These
compounds are generally secondary metabolites, and some
appear to have roles in defense against pathogens or in deterring
grazing by insect or animal herbivores. For example, resveratrol
is produced in grapes in response to fungal infection (Romero-
Pe´rez et al., 2001), whereas (as discussed above) Goat’s Rue
(a source of galegine) is classed as a noxious weed in the United
States because it is poisonous to herbivores. As discussed in
the previous section, the respiratory chain and ATP synthase
might have many potential binding sites for hydrophobic, xeno-
biotic compounds, and the production of mitochondrial poisons
might be a good general mechanism for plants to deter infection
by pathogens or grazing by herbivores. However, a side effect
of this is that many of these compounds would also be AMPK
activators and hence may have medicinal uses.
PT1
Another small molecule activator of AMPK, termed PT1, was iso-
lated via a screen of compounds that activated an AMPK-a1
construct containing just the KD and the AID (Pang et al.,
2008). The compound activated the KD-AID construct and a
complete a1b1g1 heterotrimer but failed to activate a construct
containing the KD alone, suggesting that its binding site was in
the cleft between the KD and the AID. Consistent with this,
PT1 caused phosphorylation of ACC in L6 myotubes without
altering the AMP:ATP ratio and also promoted ACC phosphory-
lation and lowered lipid content in HepG2 cells (Pang et al.,
2008).
Inhibition of AMP-Metabolizing Enzymes
An alternative approach to AMPK activation would be to inhibit
the downstream metabolism of ADP and AMP, analogous to
using inhibitors of phosphodiesterases, such as sildenafil, to
increase cyclic nucleotides. Indeed, downregulation of expres-
sion of 50-nucleotidases that convert AMP to adenosine, that
is, NT5C2 in cultured human myotubes or NT5C1A in mouse
muscle, activated AMPK and triggered ACC phosphorylation
(Kulkarni et al., 2011). The validity of this approach has also
been examined by overexpressing the 50-nucleotidase cN-IA
and the AMP deaminases AMPD1 and AMPD2 (which convert
AMP to IMP) in HEK293 cells. Overexpression of all three
enzymes decreased the activation of AMPK by oligomycin in
the cells, although overexpression of cN-IA had the largest
effect (Plaideau et al., 2012). Taken together, these results sug-
gest that 50-nucleotidase inhibitors might be useful as AMPK
activators.
Conclusions
The evidence presented in this review suggests that AMPK-
activating drugs are not only effective in treating type 2 diabetes
but might also be effective in providing protection against
cancer. If this appears ‘‘too good to be true,’’ it does not stop
there because it has recently also been suggested that AMPK
activators reduce the accumulation of the Ab peptides in celly 19, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1231
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for treatment of that disease (Salminen et al., 2011). One caveat
is that, although there is growing evidence that AMPK provides
protection against the development of cancer, it is perhaps an
unjustified leap of faith to say that AMPK activators would also
be useful in the treatment of cancer once it has arisen. Indeed,
there is now evidence that AMPK protect cells against the
metabolic stress caused by overexpression of c-Myc (Liu
et al., 2012), whereas the LKB1-AMPK pathway also protects
cultured cells against metabolic stress caused by glucose
starvation (Jeon et al., 2012). Thus, AMPK activators might be
both a ‘‘friend and foe’’ in cancer, providing protection against
its development, while at the same time making tumor cells
harder to kill using cytotoxic agents once tumors have arisen.
Although it is generally easier to develop agents that are
enzyme inhibitors rather than enzyme activators (as most indica-
tions for AMPK demand), the wide variety of agents that do
activate AMPK when applied to intact cells show that develop-
ment of AMPK activators is an achievable objective. Most of
the existing agents activate AMPK indirectly by inhibiting ATP
production, whether by inhibiting oxidative phosphorylation
(metformin, phenformin, galegine, thiazolidinediones, resvera-
trol, berberine) or glycolysis (2-deoxyglucose), thus increasing
cellular ADP:ATP and AMP:ATP ratios. Exceptions to this are
(1) AICA riboside (acadesine), a prodrug that is converted to
the active derivative, ZMP, which binds at the adenine nucleo-
tide-binding sites; (2) A-769662 and salicylate, which bind to
a common site that, although not fully defined, is distinct from
the adenine nucleotide-binding sites; and (3) PT1, which appears
to bind between the KD and the AID on the a subunit (Pang et al.,
2008). Some of these, including acadesine and A-769662, have
poor oral availability, but salicylate is orally available, and the
best bet to develop novel AMPK activators may be to target
the salicylate-binding site. Finally, one should not discount the
utility of AMPK inhibitors, although the only chemical inhibitor
targeting the kinase domain reported to date (compound C;
Zhou et al., 2001) has very poor selectivity for AMPK (Bain et al.,
2007). If AMPK does indeed protect tumor cells against cell
death induced by cytotoxic agents, then combinations of AMPK
inhibitors with cytotoxic drugs might be worth considering.ACKNOWLEDGMENTS
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